Objective: To compare the antepartum and postpartum plasma concentrations of endothelial microparticles (EMPs) in patients with pre-eclampsia with those of healthy control subjects with normal pregnancies. Methods: Plasma concentrations of EMPs were measured using specific antibody labelling and flow cytometry prior to delivery by caesarean section (antepartum), and again at 24 h and 72 h postpartum. The correlations between EMP concentration and mean arterial pressure (MAP), and between EMP concentration and 24-h urine protein were analysed. Results: A total of 59 patients with pre-eclampsia and 60 healthy control subjects participated in the study. The antepartum plasma EMP concentration was significantly higher in patients with preeclampsia than in healthy control subjects with normal pregnancies (2863.5 AE 1543.1 versus 1703.0 AE 592.2 EMPs/ml, respectively); similar findings were observed at 24 h postpartum (1836.7 AE 1153.8 versus 1421.8 AE 760.2 EMPs/ml, respectively). There was no significant difference between the two groups at 72 h postpartum. The antepartum plasma EMP concentration in patients with pre-eclampsia demonstrated a significant positive correlation with MAP (r ¼ 0.716) and with 24-h urine protein (r ¼ 0.770). Conclusion: Plasma EMP concentration might serve as a biomarker to evaluate the severity of pre-eclampsia in the future.
Introduction
Pre-eclampsia, a multiple organ dysfunction of pregnancy that is characterized by hypertension and proteinuria, develops from about 20 weeks of gestation. It often causes damage to the heart, brain, liver, kidney and other vital organs. Pre-eclampsia complicates up to 7% of pregnancies and it is one of the main causes of maternal and perinatal morbidity and mortality. 1 The exact aetiology of pre-eclampsia remains unknown, but there is evidence that a number of factors contribute to the pathogenesis of pre-eclampsia, including an inadequate blood supply to the placenta, immunological factors, heredity, endothelial cell injury and toxic factors. [1] [2] [3] The widely accepted hypothesis for the aetiology of preeclampsia is that there is insufficient trophoblast invasion, which leads to a systemic inflammatory response and endothelial dysfunction. 3 Placental hypoperfusion develops before the clinical symptoms of preeclampsia become evident. 3 The main pathophysiological changes associated with pre-eclampsia include arteriolar spasm all over the body, injury to the vascular endothelium, activation of the coagulation system, increased vascular permeability and effective hypovolaemia, with tissue hypoxia further aggravating the situation, which finally results in pathological alterations to critical organs. 4 A new marker of endothelial injury, endothelial microparticles (EMPs), which are small vesicles that result from endothelial cell membrane blebbing, has been identified. 5 EMPs play an important role in thrombosis and inflammation, as well as mediating cell-cell communication. 6 EMPs can be identified within the plasma by fluorescent antibody labelling of endothelial cell adhesion molecules retained on the surface of the liberated EMPs. 7 There is evidence that the detection of circulating EMPs allows for a direct assessment of endothelial damage. 1 Flow cytometry is the most widely used method for measuring the plasma levels of EMPs. The endothelial cell antigen profile found on EMPs has been identified as cluster of differentiation (CD)31 þ /CD42À. 1 CD31 is found at the endothelial cell junction and is involved in maintaining the integrity of the endothelium and for signalling the adhesion cascade. 8 In patients with cardiovascular and cerebrovascular diseases, the level of EMP increases abnormally and there is a positive correlation with blood pressure, which suggests that the level of EMPs is a marker that can be used to evaluate the severity of endothelial injury. 9, 10 The aim of the present study was to compare the antepartum and postpartum plasma concentrations of EMPs in patients with pre-eclampsia with those of healthy women experiencing normal pregnancies.
Patients and methods

Study population
This prospective study enrolled consecutive patients with pre-eclampsia who were admitted to the Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China, between April 2009 and February 2012. Patients were diagnosed with pre-eclampsia based on diagnostic criteria that were in accordance with guidelines from the National High Blood Pressure Working Group. 11 Patients with other complications associated with pregnancy were excluded from the study.
The control group consisted of women with normal pregnancies who were admitted during the same time period and who underwent elective caesarean section in the Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Soochow University. All of the control subjects had pregnancies that had progressed normally, normal fetal development, and no complications during their pregnancies.
All study participants provided written informed consent. Approval for collecting biological samples and for the research protocol was provided by the Committee for the Rights of Human Subjects of the Second Affiliated Hospital of Soochow University (Registration no. SDFEY20090054).
Sample collection and blood pressure measurements
All study participants were asked to provide a 24-h urine collection for the detection of proteinuria after admission to hospital. Most of the study participants were admitted to hospital by appointment prior to 08:00 hours and were asked to observe a 12-h fast prior to admission. Some patients with severe pre-eclampsia were admitted at other times, so the 24-h urine collection was started from the next morning at 08:00 hours. The participants were instructed to keep and collect all of the urine that they produced from 08:00 hours on the day of admission to 08:00 hours the next morning (24-h period). The levels of protein in the urine samples were analysed using a Pyrogallol Red kit (Beijing Strong Biotechnologies, Beijing, China) according to the manufacturer's instructions.
Peripheral venous blood (3 ml) was obtained after a 12-h fast in the morning within 24 h of hospital admission for those patients who were admitted by appointment prior to 08:00 hours, and again after a 12-h fast at 24 h postpartum and 72 h postpartum. For those patients with severe preeclampsia who were admitted at other times, the blood sample was obtained in the morning following a 12-h overnight fast. The venous blood was placed in a blood collection tube with 3.2% sodium citrate and processed immediately. The 3 ml sample of blood was separated into two Eppendorf tubes, each containing 1.5 ml and each tube was centrifuged at 160 g for 10 min at 6 C (KDC-210HR centrifuge; Anhui USTC Zonkia Scientific Instruments, Hefei, China). A 750-ml sample of platelet-rich plasma was removed from the supernatant fraction of each tube and placed into a new Eppendorf tube for the immediate detection of EMPs (see below), so that the blood sample from each study participant produced two tubes of platelet-rich plasma (750 ml per tube).
Blood pressure measurements were obtained using a mercury sphygmomanometer with patients in the supine position after 30 min of quiet rest. Mean arterial pressure (MAP) was calculated using the following formula: MAP ¼ diastolic pressure þ 1/3 pulse pressure difference (pulse pressure ¼ systolic blood pressureÀdiastolic blood pressure).
Detection of EMPs
The two 750-ml samples of platelet-rich plasma per study participant were centrifuged at 11000 g for 2 min at 6 C (KDC-210HR centrifuge; Anhui USTC Zonkia Scientific Instruments). A 600 ml sample of the supernatant fraction was collected from each tube and centrifuged at 14000 g for 45 min at 6 C (KDC-210HR centrifuge; Anhui USTC Zonkia Scientific Instruments). After centrifugation, 500 ml of the supernatant fraction was removed from each tube, and 100 ml of 0.1 mM phosphate-buffered saline (pH 7.4) was added to the remaining 100 ml precipitate. The two tubes of resuspended fluid from the same study participant were mixed together and then separated into two tubes labelled tube A and tube B. Tube A was processed as follows: 20 ml of undiluted mouse immunoglobulin (Ig)G1 K isotype control phycoerythrin (PE)-conjugated antibody and 20 ml of undiluted mouse IgG1 K isotype control fluorescein isothiocyanate (FITC)conjugated antibody (eBioscience, San Diego, CA, USA). Tube B was processed as follows: 20 ml of undiluted mouse antihuman CD31 (also known as platelet/endothelial cell adhesion molecule 1, PECAM-1) PEconjugated antibody and 20 ml of undiluted mouse antihuman CD42b FITC-conjugated antibody (eBioscience). A 100 ml aliquot of microspheres (996 microspheres/ml; AccuCheck Counting Beads; Invitrogen, Carlsbad, CA, USA) was then added to each tube and the samples were incubated at 4 C for 30 min. The samples were then analysed using a flow cytometer (BD FACSCalibur TM ; Becton, Dickinson and Co., Franklin Lakes, NJ, USA) and EMPs were defined as CD31 þ /CD42bÀ. AccuCheck counting beads are a singleplatform method for determining absolute cell counts that combines direct flow cytometric immunophenotyping with the use of two different fluorescent beads (A and B beads), which are used as a double internal standard for blood volume calculation. The methodology involves the addition of a known volume of AccuCheck counting beads to the same known volume of stained blood (or in this study, stained EMPs) in a lyse-no-wash technique. The beads were counted along with the stained EMPs using a flow cytometer and because the concentration of beads was known, the number of EMPs/ml can be calculated by relating the number of EMPs counted to the total number of fluorescent bead events. The EMP number is then multiplied by the number of total fluorospheres per unit of volume.
For the flow cytometric analyses, the forward-scattering angle and the lateral angles of the flow cytometer were set to LOG mode, and the forward-scattering angle was set for a standard microsphere with the diameter of 1.0 mm before the detection of the specimens. The duochrome method definition was as follows: EMPs <1.0 mm and CD31 þ /CD42À, stop counting after 10000 particles were collected.
The EMP concentration was calculated according to the following formula: EMP concentration ¼ (n*100*UL)/1500(R3 þ R4), where n was the standard microsphere density, UL was the number of EMPs collected by the flow cytometer, and R3 and R4 were the number of standard microspheres collected by the flow cytometer.
Statistical analyses
The plasma concentrations of EMPs are presented as mean AE SD. Normality tests and homoscedasticity analyses were undertaken (Shapiro-Wilk test (P-value > 0.05) and Levene's test of homogeneity of variance (P-value > 0.05), respectively). All data were analysed using the SPSS Õ statistical package, version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows Õ . Independentsample t-test was used after undertaking a homogeneity test of variance between two samples' mean value. The correlations between plasma EMP concentration and MAP and between plasma EMP concentration and 24-h urine protein were evaluated using Pearson's correlation coefficient analysis and linear regression analysis. A P-value < 0.05 was considered statistically significant.
Results
Fifty-nine patients with pre-eclampsia with a mean age of 29.9 AE 3.9 years (range 21-38 years), a mean gestational duration of 35.9 AE 3.6 weeks (range 26.5-39.4 weeks) when admitted to hospital, and delivery by caesarean section at a mean of 36.2 AE 3.5 weeks (range 28.3-39.5 weeks) were enrolled in the study. Sixty women with normal pregnancies with a mean age of 28.7 AE 3.5 years (range 24-33 years) and a mean gestational duration of 38.4 AE 1.5 weeks (range 37.0-42.0 weeks) who received an elective caesarean section were enrolled in the control group.
The concentration of EMPs in the plasma of patients with pre-eclampsia and in healthy control subjects with normal pregnancies were measured using flow cytometry. The antepartum concentration of plasma EMPs in patients with pre-eclampsia was significantly higher than in healthy control subjects with normal pregnancies (P < 0.05); similar findings were demonstrated at 24 h postpartum for patients with pre-eclampsia compared with healthy control subjects with normal pregnancies (P < 0.05) ( Table 1 ). There was no significant difference at 72 h postpartum in the plasma concentration of EMPs between patients with pre-eclampsia and healthy control subjects with normal pregnancies.
In patients with pre-eclampsia, the plasma concentration of EMPs at 24 h postpartum was significantly lower compared with the antepartum concentration (P < 0.05); similarly, the plasma concentration of EMPs at 72 h postpartum was significantly lower than the antepartum and the 24 h postpartum concentrations (P < 0.05). There were no significant differences in the plasma concentration of EMPs in healthy control subjects with normal pregnancies at the antepartum, 24 h postpartum and 72 h postpartum time-points.
Pearson's correlation coefficient analysis of the patients with pre-eclampsia showed a positive correlation between the antepartum plasma concentrations of EMPs and MAP (r ¼ 0.716; P < 0.05), with the linear regression equation being y ¼ 47.26x À 2509 (Figure 1 ).
Pearson's correlation coefficient analysis of the patients with pre-eclampsia demonstrated a positive correlation between the antepartum plasma concentrations of EMPs and 24-h urine protein (r ¼ 0.770; P < 0.01), with the linear regression equation being y ¼ 599.8x þ 1880 (Figure 2 ).
Discussion
The main pathophysiological change associated with pre-eclampsia is arteriolar spasm all over the body, while the key pathological step in the development of pre-eclampsia is injury to the vascular endothelium. 12, 13 The vascular endothelium is in an optimum physiological location to be able to respond to physical and chemical signals by the production of a wide range of factors that regulate vascular tone, cellular adhesion, thromboresistance, smooth muscle cell proliferation and vessel wall inflammation. 14 Once the vascular endothelium has been injured, collagen under the basement membrane becomes exposed, which may lead to adhesion of blood platelets and thrombopoiesis. 15 In response to specific stimuli, vascular endothelial cells produce a series of cytokines that regulate vascular tension, thrombosis, cell proliferation and inflammatory reactions. 16 It has been shown that levels of endothelial adhesion molecules such as vascular cell adhesion molecule 1, intercellular adhesion molecule 1, CD31, E-selectin and fibronectin are increased in the peripheral blood of patients with pre-eclampsia, which results in the accumulation of inflammatory cells and inflammatory factors on the surface of injured endothelial cells, aggravating existing endothelial injury and producing a vicious cycle of pathological events. 17 In addition to the soluble factors, microparticles are shed from the plasma membranes of the endothelial cells. 18 Circulating microparticles are a heterogeneous group of small membrane-coated vesicles with a diameter of 0.1-1 mm. 5 They can originate from platelets, B and T lymphocytes, antigen-presenting cells and neutrophils. 19 EMPs originate from endothelial cells and are considered to be a sensitive and specific marker of the degree of injury to the endothelial cells. 3 EMPs produced by endothelial cells express different membrane antigens, including CD31, CD51 and CD62E compared with membrane microparticles derived from other cell types. 20 CD62E is expressed only on EMPs derived from activated endothelial cells and not on EMPs derived following endothelial apoptosis, while antigens CD31 and CD51 are usually considered to be stable markers of EMPs. 1 CD31 is a more sensitive marker of vascular injury than CD51. 21, 22 Since platelets can also express CD31, CD42b was used to exclude the influence of platelets. In this present study, EMPs were defined as CD31 þ /CD42bÀ, which objectively identifies peripheral blood EMPs in patients. 23 The results of the present study showed that the antepartum plasma concentration of EMPs was significantly higher in patients with pre-eclampsia compared with healthy control subjects with normal pregnancies, but the concentration decreased significantly at 24 h postpartum in patients with preeclampsia. These current findings were in agreement with those of Marques et al. 24 , who reported that EMP counts were increased in patients with severe pre-eclampsia. Higher concentrations of EMPs were demonstrated in eclamptic and severe preeclamptic patients compared with patients with mild pre-eclampsia. 25 The concentration of EMPs was higher in women with preeclampsia than in women with gestational hypertension and normal pregnancies. 8 In addition to these previous clinical findings, emerging evidence suggests that EMPs themselves may contribute to the pathological processes. 26 Thus, EMPs appear to serve as both markers and mediators of endothelial pathology. 27 Elevation of EMPs in the maternal circulation appears to be greatly accelerated in pre-eclampsia and may contribute to and aggravate maternal vascular injury. 28 The levels of EMPs decrease after delivery since the endothelial cells are no longer activated after removal of the cause of the injury to the vascular endothelium. 1 In the present study, the concentration of EMPs continued to decrease up to 72 h postpartum when there was no significant difference between patients with pre-eclampsia and healthy control subjects with normal pregnancies, demonstrating that delivery by caesarean section was the best strategy to improve vascular endothelial function. In the healthy control subjects with normal pregnancies, there were no significant differences in the plasma concentration of EMPs at the antepartum, 24 h postpartum and 72 h postpartum time-points in the present study. In a previous study of 20 pre-eclamptic women and 20 healthy control subjects, endothelial damage, as demonstrated by EMP levels measured using flow cytometry, was shown to persist 1 week after delivery. 1 More research will need to be undertaken to confirm the varying pattern of EMPs in the postpartum period.
The present study provides further evidence on the relationship between EMPs and blood pressure and 24-h urine protein.
The present findings demonstrated a significant positive correlation between the antepartum plasma concentration of EMPs and MAP in patients with pre-eclampsia, which supports the suggestion that higher blood pressure is associated with more severe endothelial damage. The present findings also demonstrated a significant positive correlation between the antepartum plasma concentration of EMPs and 24-h urine protein in patients with pre-eclampsia. As a result of the whole system arteriolar spasm and vascular endothelial damage that is associated with pre-eclampsia, it seems likely that the glomerulus would also be involved. Injury to the glomerulus and kidney nephrons during pre-eclampsia can lead to proteinuria, which decreases after delivery with the recovery of the vascular endothelial injury. 29 Nomura et al. 30 found that when benidipine and nifedipine were used to treat hypertension in patients with diabetes, not only was blood pressure lowered, but the concentration of EMPs was also lowered. Other research has demonstrated that the formation of EMPs is a calcium-dependent process and that a calcium antagonist can inhibit the release of EMPs to some extent. 30, 31 Fluvastatin suppressed the release of EMPs from tumour necrosis factor-a-activated cultured human coronary artery endothelial cells, which suggests that statins can restore endothelial function and reduce release of EMPs at the same time as lowering blood pressure. 32 In conclusion, this present study demonstrated that the antepartum plasma concentration of EMPs was significantly higher in patients with pre-eclampsia compared with healthy control subjects with normal pregnancies. The present study also demonstrated a significant positive correlation between the antepartum plasma concentration of EMPs and MAP, and between the antepartum plasma concentration of EMPs and 24-h urine protein. The plasma concentration of EMPs significantly decreased at 24 h postpartum in patients with pre-eclampsia and continued to decrease up to 72 h postpartum, by which time the concentration was not significantly different from that in the healthy control subjects with normal pregnancies. Further research is required to determine the direct interaction between plasma EMPs and endothelial injury, but these current findings suggest that EMPs might serve as a biomarker to evaluate the severity of pre-eclampsia in the future.
